// App-Quantinova.ai

P196 : Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure

Researchers

Presenter

  • Nice, R

Principal Investigators

  • Goodhand, J.R

  • Kennedy, N

  • Ahmad, T

  • Winyard, P

  • McDonald, T.J

Medical Centers

  • Royal Devon & Exeter NHS Foundation Trust, Blood Sciences, Exeter, United Kingdom

  • University of Exeter , Medical School, Exeter, United Kingdom

  • Royal Devon & Exeter NHS Foundation Trust, Blood Sciences, Exeter, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Infliximab

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved